GLP1R and obesity due to melanocortin 4 receptor deficiency: In the United States, GLP-1 RAs such as liraglutide and semaglutide have been licensed by the US Food and Drug Administration (FDA) for the treatment of obesity and excessive weight, regardless of whether the patient has diabetes.